Welcome to our dedicated page for Xeris Biopharma Holdings news (Ticker: XERS), a resource for investors and traders seeking the latest updates and insights on Xeris Biopharma Holdings stock.
Xeris Biopharma Holdings, Inc. reports news about its commercial biopharmaceutical business, including product revenue, financial guidance and operating updates tied to Recorlev®, Gvoke® and Keveyis®. The company commercializes Recorlev for endogenous Cushing’s syndrome, Gvoke ready-to-use liquid glucagon for severe hypoglycemia and Keveyis for primary periodic paralysis.
Recurring updates also cover development of XP-8121, a Phase 3-ready once-weekly subcutaneous levothyroxine candidate for hypothyroidism, and programs using Xeris’ XeriSol® and XeriJect® technology platforms. Company news includes intellectual property developments for Recorlev, partnership-related revenue, and equity inducement grants under Nasdaq listing rules.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Xeris Biopharma Holdings (NASDAQ: XERS) has received a new patent (US Patent Number 11,590,205) from the U.S. Patent and Trademark Office, covering formulations within its Gvoke® product line for treating hypoglycemia. This patent reinforces Xeris' intellectual property strategy, bolstering its XeriSol™ platform. The company boasts a robust patent portfolio of 178 patents globally, with 33 issued in the U.S., and additional applications pending. The CEO, Paul R. Edick, emphasized the significance of this patent in enhancing the company’s market position. Xeris is committed to developing innovative therapies, with existing products including Gvoke®, Keveyis®, and Recorlev®, and a diverse pipeline aimed at various human diseases.
Xeris Biopharma Holdings (Nasdaq: XERS) has entered a collaboration with Regeneron Pharmaceuticals to utilize its XeriJect™ platform for developing concentrated subcutaneous injections of two undisclosed monoclonal antibodies. The agreement includes an upfront payment and potential milestone payments based on preclinical achievements. Regeneron retains the option to commercially license the Xeris technology and nominate additional molecules for reformulation. XeriJect™ offers ready-to-use, high-drug-loaded suspensions, addressing patient needs in drug delivery. This partnership is a part of Xeris' ongoing collaborations with major biopharmaceutical firms.